DT Cloud Star Acquisition Corp（DTSQ）股票分析

AI 分析 of DT Cloud Star Acquisition Corp (DTSQ)

持有

Currently, DTSQ is not a strong buy due to its high valuation metrics and recent negative earnings trends. The stock is trading at a price of 11.55, with a forward P/E of 0, indicating uncertainty in future earnings. The RSI is at 61.51, suggesting it is nearing overbought territory. While the recent merger with PrimeGen could provide potential growth, the stock has shown a lack of momentum with a 5-day change of 0.00% and a 20-day change of +0.70%. The primary risk is the declining net income trend, with a significant drop to -110,289 in Q1 2026, which raises concerns about its financial health.

估值指标

DT Cloud Star Acquisition Corp（DTSQ）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。

预期市盈率

严重低估

5 年均值 P/E

0.00

当前P/E

0.00

高估

0.00

低估

0.00

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

合理

5 年均值 P/S

0.05

当前P/S

0.00

高估

0.82

低估

-0.71

Alphio AI 对 DTSQ 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%DTSQ

$12.49

情景价格

基

基准

基准 · 50%DTSQ

$11.53

情景价格

悲

悲观

悲观 · 25%DTSQ

$9.81

情景价格

持有 DTSQ 的大户

W

W. R. Berkley Corporation

+ 持有DTSQ

+4.37%

3个月收益率

DTSQ 常见问题 —— 由 Alphio AI 解答

DT Cloud Star Acquisition Corporation is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has no operations and has not generated any revenue. It operates in the Financials sector.

Currently, DTSQ is not a strong buy due to its high valuation metrics and recent negative earnings trends. The stock is trading at a price of 11.55, with a forward P/E of 0, indicating uncertainty in future earnings. The RSI is at 61.51, suggesting it is nearing overbought territory. While the recent merger with PrimeGen could provide potential growth, the stock has shown a lack of momentum with a 5-day change of 0.00% and a 20-day change of +0.70%. The primary risk is the declining net income trend, with a significant drop to -110,289 in Q1 2026, which raises concerns about its financial health.